All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Cysticercosis (CC) is a parasitic infection caused by the larva stage (c*ysticercus)* of the tapeworm *Taenia solium*. It has been a major public health problem since historical times \[[@pntd.0005153.ref001]\], and remains so, particularly in the developing world (low-and middle-income countries; LMIC), due to inadequate hygiene, rudimentary pig management and slaughter, and poor waste water management \[[@pntd.0005153.ref002]\]. Developed regions such as Europe and North America are considered to be virtually free of endemic transmission, although there remains a substantial disease burden in these regions due to migration \[[@pntd.0005153.ref003]\]. Neurocysticercosis (NCC) is considered a common helminthic infection of the central nervous system (CNS) across Latin America, Sub-Saharan Africa and Asia \[[@pntd.0005153.ref004]--[@pntd.0005153.ref007]\], and a common cause of late-onset epilepsy in LMIC \[[@pntd.0005153.ref004],[@pntd.0005153.ref005],[@pntd.0005153.ref008]\]. For instance, a study in Burundi showed a strong link between CC and epilepsy, with an etiologic fraction of 50% (95% CI: 42--57) and an odds ratio of 3.8 (95% CI: 2.5 to 5.1) \[[@pntd.0005153.ref006]\]. It was estimated in a recent meta-analysis that people infected with CC in Sub-Saharan Africa (SSA) are at 3.4--3.8 fold greater risk of having epilepsy \[[@pntd.0005153.ref007]\]. It is noted that despite the importance of these diseases at an individual and population level, there are still discrepancies in the literature about their precise impact \[[@pntd.0005153.ref004]\]. Moreover, earlier reviews focused on specific regions alone \[[@pntd.0005153.ref007]\]. We conducted a review of studies that analyzed CC, NCC, and epilepsy across Latin America, Asia and Africa, to estimate the probability and etiologic fraction of epilepsy due to CC in tropical regions.

Methods {#sec006}
=======

Literature search {#sec007}
-----------------

Systematic searches were conducted for articles in English and French using the following databases: Medline, Scopus, Science Direct, Ingenta Connect, Refdoc (formerly Article Science). We also searched for articles and theses in the bibliographic database of the Institut d'Epidemiologie et de Neurologie Tropicale <http://www.unilim.fr/ient/>. Keywords used were (cysticercosis OR *Taenia solium* OR neurocysticercosis) AND epilepsy. Logical operators (AND, OR, NOT) were used. Bibliographies of published reviews and meta-analyses were also searched.

### Data extraction {#sec008}

Two reviewers (GD and PMP) extracted data using methodology applied in previous meta-analyses \[[@pntd.0005153.ref007]\] that focused on sub-Saharan Africa. Data types collected included; General: authors, year of publication, country, and study design used. Epilepsy: case sources, definition used, how and who confirmed epilepsy, source of people without epilepsy i.e. controls, and matching criteria. *CC*: methods used to evaluate CC and NCC (serological tests including enzyme-linked immunoelectrotransfer blot-EITB and enzyme-linked immunosorbent assay-ELISA, as well as neuroimaging) Methods: sample size for the following four groups: people with epilepsy affected by cysticercosis (PWE + CC), people with epilepsy not affected by cysticercosis (PWE---CC), people without epilepsy affected by cysticercosis (PWOE + CC), people without epilepsy unaffected by cysticercosis (PWOE---CC).

Eligible studies included those that 1) had epilepsy as a disease of interest and cysticercosis as exposure, 2) estimated sample size using appropriate techniques, 3) included detailed methods for diagnosis and determination of exposure, and 4) included a **control group in the analysis**. Case-reports, notes, letters to the editor, scientific reviews and other meta-analyses were excluded at this stage. For manuscripts in which authors presented results for multiple methods, we followed an order of priority. For instance, we considered computed tomography (CT) results more relevant than EITB or ELISA assays, and we retained EITB in preference to ELISA.

Subgroup analyses {#sec009}
-----------------

We conducted three subgroup analyses by taking into account those studies that used specific diagnostic tools for CC or NCC and epilepsy. The first group comprised studies that used EITB to determine CC exposure. The second analysis included studies that used brain CT scan to assess NCC exposure. The third analysis involved studies that had used standardized diagnostic methods to confirm epilepsy in population-based studies, such as neurological surveys applied in a door-to-door fashion with evaluation by well-trained general practitioners and /or neurological evaluation to confirm cases, and including at least one matched control per case. Finally, we performed an analysis by continent.

Statistical analysis {#sec010}
--------------------

For each of the selected studies, the odds ratio (OR) and its 95% confidence interval was determined using Epi-Info 6 (Centers for Disease Control and Prevention, Atlanta, USA). A meta-analysis was used to estimate the risk of developing epilepsy when exposed to CC, applying a random-effects model using Stata software, version 10.1 (Stata-Corp, College Station, TX, USA) to account for the variance of each included study \[[@pntd.0005153.ref009]\]. Odds ratios (OR) and 95% confidence intervals (95% CIs) were determined. Homogeneity was assessed by I squared tests. Subgroup analyses were also conducted for studies ascertaining CC by EITB assays, CT scan and those studies that followed certain requirements for determining epilepsy (as mentioned under Methods, above). Because epilepsy has multiple causes and associated factors, we calculated the etiologic fraction (EF) i.e. the proportion of cases "attributable" to cysticercosis, by comparing the prevalence among exposed and the unexposed. The EF provided an unadjusted estimate of the proportion of cases of epilepsy that could be prevented if exposure to CC were eliminated. The etiologic fraction was based on the pooled estimate of risk, rather than single risk estimates for individual studies, by using the following formula: proportion exposed (common OR-1)/proportion exposed (common OR-1) +1.

Results {#sec011}
=======

In total, our searches identified 1709 publications. Of these, 1287 articles were excluded at the title level and 350 at the abstract level because they did not meet the inclusion criteria. Seventy-six articles were read in entirety; 37 were found to meet inclusion criteria and were included in the analysis (see [Fig 1](#pntd.0005153.g001){ref-type="fig"}). These 37 studies (see [Fig 2](#pntd.0005153.g002){ref-type="fig"}) were conducted in 23 different countries (five countries each from Asia and Latin America, and 13 from Africa). In total, these 37 studies covered 24,646 subjects (14,934 PWOE and 9,712 PWE). Seventy eight percent (29/37) were case-control studies, of which 14/29 (48.27%) were matched studies, (see [Table 1](#pntd.0005153.t001){ref-type="table"}).

![Flowchart of literature search.](pntd.0005153.g001){#pntd.0005153.g001}

![Locations of studies that evaluated association of cysticercosis and epilepsy.](pntd.0005153.g002){#pntd.0005153.g002}
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###### Description of the methods used in studies seeking an association between cysticercosis and epilepsy, classified by year of publication.

![](pntd.0005153.t001){#pntd.0005153.t001g}

                                                         People with epilepsy                          People without epilepsy   Exposure                                                                                                                                                                             
  ------------------------------------------------------ --------------------------------------------- ------------------------- -------------------- ----- --------------------------------------------- -------------- -------- ------------ ------------------------ -------------------------- ------------------ ---------------------
  Chopra, 1981 \[[@pntd.0005153.ref022]\]                India                                         Asia                      Southern Asia        CCS   Hospital                                      NS             NS       GenPop       None                     Cranial X-Ray, HAT         (+) HAT            (+)Cranial X-ray
  Maldonado, 1986 \[[@pntd.0005153.ref011]\]             La Réunion                                    Africa                    Eastern Africa       CCS   Hospital                                      NS             NS       Hospital     None                     X-Ray st                   Calcified Lesion   None
  Mignard, 1986 \[[@pntd.0005153.ref023]\]               La Réunion                                    Africa                    Eastern Africa       CCS   Hospital                                      NS             CK       Hospital     None                     ELISA, CT                  (+) ELISA          (+) CT
  Dumas, 1989 \[[@pntd.0005153.ref024]\]                 Togo                                          Africa                    Western Africa       CSS   GenPop                                        NS             Neurol   GenPop       House ^a^                Bx, Cranial X-ray, ELISA   (+) ELISA/His      (+) Cranial X-ray
  Gracia, 1990 \[[@pntd.0005153.ref025]\]                Panama                                        America                   Central America      CCS   GenPop                                        ILAE 1970      Neurol   GenPop       sex, age \>5             WB                         (+)WB              None
  Dansey, 1992 \[[@pntd.0005153.ref026]\]                South Africa                                  Africa                    South Africa         CCS   Miners                                        NS             CE       Miners       None                     CT                         None               (+) CT
  Nzisabira, 1992 \[[@pntd.0005153.ref027]\]             Burundi                                       Africa                    Eastern Africa       CCS   GenPop                                        NS             Neurol   GenPop       None                     ELISA (CSF), CT,Bx         (+)ELISA           (+)ELISA/(+) CT
  Sarti, 1992 \[[@pntd.0005153.ref028]\]                 Mexico                                        America                   North America        CSS   GenPop                                        NS             NS       GenPop       None                     EITB                       (+)EITB            None
  García, 1993 \[[@pntd.0005153.ref029]\]                Peru                                          America                   South America        CCS   Hospital                                      NS             Neurol   Hospital     None                     EITB                       (+)EITB            None
  Kong, 1993 \[[@pntd.0005153.ref030]\]                  Korea                                         Asia                      Eastern Asia         CCS   GenPop[\*](#t001fn006){ref-type="table-fn"}   NS             NS       GenPop       None                     ELISA                      (+)ELISA           None
  Bouteille, 1994 \[[@pntd.0005153.ref031]\]             Benin                                         Africa                    Western Africa       CSS   GenPop ^a^                                    ILAE 1993      Neurol   GenPop       None                     Bx, ELISA                  (+)ELISA/His       None
  Theis, 1994 \[[@pntd.0005153.ref032]\]                 Indonesia                                     Asia                      South-Eastern Asia   CCS   Hospital                                      NS             NS       GenPop       None                     ELISA, EITB                (+) Elisa/EITB     None
  Aranda-Alvarez, 1995 \[[@pntd.0005153.ref033]\]        Mexico                                        America                   North America        CSS   GenPop ^b^                                    NS             NS       GenPop ^b^   None                     ELISA-Ag                   (+)ELISA-Ag        None
  Grill, 1996 \[[@pntd.0005153.ref034]\]                 Madagascar                                    Africa                    Eastern Africa       CCS   Hospital ^a^                                  NS             Neurol   Hospital     None                     CT, ELISA /EITB (CSF)      (+) ELISA/EITB     (+) ELISA /EITB /CT
  Andriantsimahavandy, 1997 \[[@pntd.0005153.ref008]\]   Madagascar                                    Africa                    Eastern Africa       CCS   Hospital                                      OMS 1981       CK       Hospital     Province, sex, age\>10   EITB (CSF/ser)             (+)EITB            (+)EITB (CSF)
  Handali, 1997 \[[@pntd.0005153.ref035]\]               Indonesia                                     Asia                      South-Eastern Asia   CSS   GenPop                                        NS             NS       GenPop       None                     Bx                         Cyst presence      None
  Newell, 1997 \[[@pntd.0005153.ref012]\]                Burundi                                       Africa                    Eastern Africa       CCS   MR                                            NE             MD       Family       Household                ELISA-Ag, EITB             (+)ELISA-Ag/EITB   None
  Correa, 1999 \[[@pntd.0005153.ref036]\]                Mexico                                        America                   North America        CCS   GenPop                                        NS             NS       GenPop       None                     ELISA-Ag, EITB             (+)ELISA-Ag/EITB   None
  Cruz, 1999 \[[@pntd.0005153.ref037]\]                  Ecuador                                       America                   South America        CCS   GenPop                                        ILAE 1993      Neurol   GenPop       None                     EITB, CT                   (+)EITB            (+) CT
  Balogou, 2000 \[[@pntd.0005153.ref038]\]               Togo                                          Africa                    Western Africa       CSS   GenPop                                        ILAE 1993      Neurol   GenPop       None                     Bx, Cranial X-ray, ELISA   (+) ELISA/His      (+) Cranial X-ray
  Mittal, 2001 \[[@pntd.0005153.ref039]\]                India                                         Asia                      Southern Asia        CCS   Hospital                                      NS             NS       NE           None                     ELISA                      (+)ELISA           None
  Nicoletti, 2002 \[[@pntd.0005153.ref013]\]             Bolivia                                       America                   South America        CCS   GenPop                                        ILAE 1993      Neurol   GenPop       Villa, sex, age \>5      EITB                       (+)EITB            None
  Macharia, 2002 \[[@pntd.0005153.ref040]\]              Kenya                                         Africa                    Eastern Africa       CCS   Hospital                                      ILAE 1993      CK       Hospital     Province,age,sex         ELISA                      (+)ELISA           None
  Rakatobe, 2002 \[[@pntd.0005153.ref041]\]              Madagascar                                    Africa                    Eastern Africa       CCS   GenPop                                        ILAE 1989      Neurol   GenPop       Family                   ELISA, WB                  (+) WB             None
  Nsengiyumva, 2003 \[[@pntd.0005153.ref006]\]           Burundi                                       Africa                    Eastern Africa       CCS   Hospital                                      ILAE 1993      Neurol   Hospital     Province,age             ELISA                      (+)ELISA           None
  Dongmo, 2004 \[[@pntd.0005153.ref042]\]                Cameroun                                      Africa                    Middle Africa        CCS   GenPop ^a^                                    ILAE 1993      Neurol   GenPop       Age \> 5                 ELISA                      (+)ELISA           None
  Del Brutto, 2005 \[[@pntd.0005153.ref043]\]            Ecuador                                       America                   South America        CCS   GenPop                                        ILAE 1989      Neurol   GenPop       Sex, age \> 5            WB, CT                     (+)WB              (+) CT
  Montano, 2005 \[[@pntd.0005153.ref044]\]               Peru                                          America                   South America        CSS   GenPop                                        ILAE 1989      Neurol   GenPop       None                     EITB, CT                   (+)EITB            (+) CT
  Li, 2006 \[[@pntd.0005153.ref045]\]                    China                                         Asia                      Eastern Asia         CSS   GenPop                                        NS             MD       GenPop       None                     ELISA                      (+)ELISA           None
  Tran, 2007 \[[@pntd.0005153.ref046]\]                  Laos                                          Asia                      South-Eastern Asia   CCS   GenPop                                        ILAE 1993      Neurol   GenPop       Villa, sex, age \> 5     ELISA, WB                  (+) ELISA/WB       None
  Prasad, 2008 \[[@pntd.0005153.ref047]\]                India                                         Asia                      Southern Asia        CCS   GenPop                                        ILAE 1993      NS       Family       Family                   EITB, MRI                  (+)EITB            (+) MRI
  Winkler, 2009 \[[@pntd.0005153.ref010]\]               Tanzanie                                      Africa                    Eastern Africa       CCS   Hospital ^b^                                  Winkler 2007   Neurol   Hospital     None                     ELISA (CSF,Ser), CT        (+)ELISA           (+)ELISA(CSF)/ CT
  Secka, 2010 \[[@pntd.0005153.ref048]\]                 Gambia                                        Africa                    Western Africa       CCS   Hospital, MR                                  ILAE 1989      NS       GenPop       Villa, sex, age \> 5     ELISA-Ag, EITB, CT         (+)ELISA-Ag/EITB   (+) CT
  Nitiéma, 2012 \[[@pntd.0005153.ref049]\]               Burkina Faso                                  Africa                    Western Africa       CCS   GenPop ^c^                                    ILAE 2006      MD       GenPop ^c^   None                     ELISA-Ag                   (+)ELISA-Ag        None
  Singh, 2012 \[[@pntd.0005153.ref050]\]                 India                                         Asia                      Southern Asia        CCS   GenPop ^a^                                    ILAE 1989      Neurol   GenPop ^a^   Sex, age \> 2            EITB                       (+)EITB            None
  Elliott, 2013 \[[@pntd.0005153.ref051]\]               Cameroun                                      Africa                    Middle Africa        CCS   MR                                            ILAE 1989      MD       GenPop       Sex, age                 EITB                       (+)EITB            None
  Ngugi, 2013 \[[@pntd.0005153.ref052]\]                 Kenya [\*](#t001fn006){ref-type="table-fn"}   Africa                    Eastern Africa       CCS   GenPop ^d^                                    ILAE 1989      MD       GenPop ^d^   Age                      WB                         (+)WB              None

Source, NS: non-specific, GenPop: general population, GP\*: population from Charity centers, GenPop a: General population older than 5 years old, GenPop b: General Population older than 14 years old. GenPop c: General Population older than 7 years old, GenPop d: General Population followed by centers for surveillance of health and demographic, Hospital a: Hospital Population older than 1 year old, Hospital b: Hospital Population older than 5 years old, MR: Medical Records.

Criteria, House a: House & Neighborhood. Confirmation, CK: cases know from local health centers, CE: clinical evaluation, MD: medical doctor, Neurol: neurologist.

HAT: hemagglutination test, X-Ray st: X-Ray soft Tissue, WB: Western Blot, Bx: Biopsy, His: Histology, Elisa-Ag: Elisa Antigen, Ser: serum, CSF: Cerebro Spinal Fluid

CT: computed tomography of the brain, MRI: Magnetic Resonance of the Brain

Kenia

\*: Kenya, Sud-Africa, Uganda, Tanzania, Ghana.

CSS: cross-sectional study, CCS: case-control studies, Conf: confirmation, Criteria: selection criteria

Epilepsy, CC and NCC {#sec012}
--------------------

Twenty studies defined epilepsy, of which 18/20 (90%) followed at least one definition recommended by the International League against Epilepsy (ILAE, 1981, 1989, 1993, 2006). One study each used definitions proposed by the World Health Organization and that recommended for LMICs \[[@pntd.0005153.ref010]\]. As noted in **[Table 1](#pntd.0005153.t001){ref-type="table"}**, there was great variability in the tools used for assessing exposure to CC, ranging from physical examination of subcutaneous nodules to Computed Tomography of the brain (CT), MRI images, cyst histology, and bioassays in serum or cerebrospinal fluid (CSF).

A total of 21/37 (56.75%) studies determined exposure to CC by detecting antibodies or antigens in serum using ELISA or ELISA-Ag. Seven studies used EITB to confirm or refute the results of ELISA and 12 studies used only EITB to determine CC exposure. One study used a hemagglutination test with sheep red blood cells sensitized to cysticercus antigens to determine exposure to CC. NCC exposure was determined by measuring antibodies in the CSF, but only 5/37 studies (13.51%) did so, by using ELISA (n = 3) or EITB (n = 2). CT was used in 14 studies, including 13 to assess NCC, and one \[[@pntd.0005153.ref011]\] focused on the soft parts of the thigh.

Association between CC and epilepsy {#sec013}
-----------------------------------

As shown in **[Table 2](#pntd.0005153.t002){ref-type="table"}**, the association between CC and epilepsy was statistically significant in 19 studies, leaving 18 with a non-significant association. The association was in fact nearly significant for two studies \[[@pntd.0005153.ref012],[@pntd.0005153.ref013]\]. Odds ratios ranged from 0.2 to 25.4 and the *a posteriori* statistical power ranged from 4.5% to 100.0%.

10.1371/journal.pntd.0005153.t002

###### Results obtained in studies looking for an association between cysticercosis and epilepsy classified by year of publication.

![](pntd.0005153.t002){#pntd.0005153.t002g}

                                                         PWE    PWOE   PWE CC+                                  PWOE CC+   SP                                                                         
  ------------------------------------------------------ ------ ------ ---------------------------------------- ---------- ---------------------------------------- ------ ------ ------------------- ----------
  Chopra, 1981 \[[@pntd.0005153.ref022]\]                771    98     267                                      25.7       2                                        2      100    25.4 (6.2--104.0)   \< 0.001
  Maldonado, 1986 \[[@pntd.0005153.ref011]\]             240    385    40                                       16.7       19                                       5      99.9   3.9 (2.2--6.8)      \< 0.001
  Mignard, 1986 \[[@pntd.0005153.ref023]\]               242    385    45                                       18.6       32                                       8.3    96.9   2.5 (1.6--4.1)      \< 0.001
  Dumas, 1989 \[[@pntd.0005153.ref024]\]                 88     1439   27                                       30.7       98                                       6.8    100    6.1 (3.7--10.0)     \< 0.001
  Gracia, 1990 \[[@pntd.0005153.ref025]\]                19     36     1[\*](#t002fn001){ref-type="table-fn"}   5.3        1[\*](#t002fn001){ref-type="table-fn"}   2.8    6.6    1.9 (0.1--32.9)     0.772
  Dansey, 1992 \[[@pntd.0005153.ref026]\]                165    138    63                                       38.2       20                                       14.5   99.5   3.6 (2.1--6.4)      \< 0.001
  Nzisabira, 1992 \[[@pntd.0005153.ref027]\]             98     30     40                                       40.8       1[\*](#t002fn001){ref-type="table-fn"}   3.3    96.9   20.0 (2.6--152.9)   \< 0.001
  Sarti, 1992 \[[@pntd.0005153.ref028]\]                 16     1533   5                                        31.3       162                                      10.6   67.8   3.9 (1.3--11.2)     0.245
  Kong, 1993 \[[@pntd.0005153.ref030]\]                  189    309    22                                       11.6       8                                        2.6    98.6   1.9 (1.1--3.3)      0.018
  Garcia, 1993 \[[@pntd.0005153.ref029]\]                2667   750    108                                      4.1        16                                       2.1    66.4   5.0 (2.2--11.4)     \< 0.001
  Bouteille, 1994 \[[@pntd.0005153.ref031]\]             22     1421   2                                        9.1        55                                       3.9    21.2   2.5 (0.6--10.9)     0.49
  Theis, 1994 \[[@pntd.0005153.ref032]\]                 74     746    10                                       13.5       94                                       12.6   4.5    1.1 (0.5--2.2)      0.967
  Aranda-Alvarez, 1995 \[[@pntd.0005153.ref033]\]        46     854    3                                        6.5        6                                        0.7    92.7   9.9 (2.4--40.8)     0.002
  Grill, 1996 \[[@pntd.0005153.ref034]\]                 256    113    153                                      59.8       30                                       26.5   100    4.1 (2.5--6.7)      \< 0.001
  Andriantsimahavandy, 1997 \[[@pntd.0005153.ref008]\]   104    104    33                                       31.7       14                                       13.5   88.6   3.0 (1.5--6.0)      0.003
  Handali, 1997 \[[@pntd.0005153.ref035]\]               241    260    163                                      67.6       215                                      82.7   99.2   0.4 (0.3--0.7)      \< 0.001
  Newell, 1997 \[[@pntd.0005153.ref012]\]                103    72     12                                       11.7       2                                        2.8    56.8   4.6 (1.0--21.3)     0.065
  Cruz, 1999 \[[@pntd.0005153.ref037]\]                  26     118    14                                       53.8       17                                       14.4   99.4   7.0 (2.7--17.5)     \< 0.001
  Correa, 1999 \[[@pntd.0005153.ref036]\]                68     133    15                                       22.1       17                                       12.8   38     1.9 (0.9--4.2)      0.134
  Balogou, 2000 \[[@pntd.0005153.ref038]\]               115    1343   12                                       10.4       37                                       2.8    99.1   4.1 (2.1--8.1)      \< 0.001
  Mittal, 2001 \[[@pntd.0005153.ref039]\]                1881   50     196                                      10.4       1[\*](#t002fn001){ref-type="table-fn"}   2      96.1   5.7 (0.8--41.5)     0.088
  Nicoletti, 2002 \[[@pntd.0005153.ref013]\]             113    233    22                                       19.5       27                                       11.6   47     1.8 (1.0--3.4)      0.071
  Macharia, 2002 \[[@pntd.0005153.ref040]\]              99     124    5                                        5.1        3                                        2.4    19.1   2.2 (0.5--9.2)      0.492
  Rakatobe, 2002 \[[@pntd.0005153.ref041]\]              99     107    2                                        2          13                                       12.1   72.4   0.2 (0.1--0.7)      0.011
  Nsengiyumva, 2003 \[[@pntd.0005153.ref006]\]           324    648    193                                      59.6       204                                      31.5   100    3.2 (2.4--4.2)      \< 0.001
  Dongmo, 2004 \[[@pntd.0005153.ref042]\]                93     81     17                                       18.3       12                                       14.8   9.3    1.3 (0.6--2.9)      0.683
  Del Brutto, 2005 \[[@pntd.0005153.ref043]\]            19     19     5                                        26.3       1                                        5.3    42.8   6.4 (0.7--61.5)     0.182
  Montano, 2005 \[[@pntd.0005153.ref044]\]               39     111    15                                       38.5       26                                       23.4   41.8   2.0 (0.9--4.5)      0.109
  Li, 2006 \[[@pntd.0005153.ref045]\]                    55     445    9                                        16.4       11                                       2.5    99.9   7.7 (3.0--19.6)     \< 0.001
  Tran, 2007 \[[@pntd.0005153.ref046]\]                  31     124    1[\*](#t002fn001){ref-type="table-fn"}   3.2        6                                        4.8    5.2    0.7 (0.1--5.7)      0.923
  Prasad, 2008 \[[@pntd.0005153.ref047]\]                60     107    29                                       48.3       31                                       28.9   70.9   2.3 (1.2--4.4)      0.02
  Winkler, 2009 \[[@pntd.0005153.ref010]\]               212    198    38                                       17.9       10                                       5.1    98.2   4.1 (2.0--8.5)      \< 0.001
  Secka, 2010 \[[@pntd.0005153.ref048]\]                 210    420    1[\*](#t002fn001){ref-type="table-fn"}   0.5        1[\*](#t002fn001){ref-type="table-fn"}   0.2    6.6    2.0 (0.1--32.2)     0.802
  Nitiéma, 2012 \[[@pntd.0005153.ref049]\]               39     814    5                                        12.9       28                                       3.4    67.1   4.1 (1.5--11.4)     0.022
  Singh, 2012 \[[@pntd.0005153.ref050]\]                 106    106    27                                       25.5       13                                       12     77.7   2.4 (1.2--5.1)      0.011
  Elliott, 2013 \[[@pntd.0005153.ref051]\]               249    245    11                                       4.4        13                                       53     7.6    0.8 (0.4--1.9)      0.803
  Ngugi, 2013 \[[@pntd.0005153.ref052]\]                 533    835    15                                       28.1       18                                       21.5   52.7   1.3 (0.7--2.6)      0.533

\*Result = 0 in the study, modified to calculate the odds ratio, otherwise OR independent, SP: a posteriori statistical power

OR: Odds ratio, PWE + CC: people with epilepsy affected by cysticercosis, PWE---CC: people with epilepsy not affected by cysticercosis, PWOE + CC: people without epilepsy affected by cysticercosis, PWOE--CC: people without epilepsy unaffected by cysticercosis

Meta-analysis and subgroup analyses {#sec014}
-----------------------------------

A meta-analysis of 37 studies based on the determination of exposure through detection of antibodies by ELISA or EITB, antigen detection by ELISA, or CT findings, is shown in [Fig 3](#pntd.0005153.g003){ref-type="fig"}. The common odds ratio was estimated to be 2.7 (95% CI 2.1--3.6), p\<0.001. Heterogeneity was substantial with a I squared at 78% (p\<0.0001).

![Meta-analysis assessing the association between CC and epilepsy globally and by continents: OR (odds ratio) of each study and common OR estimated using a random effects model](pntd.0005153.g003){#pntd.0005153.g003}

Three subgroup analyses were also performed as detailed in the methods section above. The first was based on studies that used EITB (n = 19), [Fig 4A](#pntd.0005153.g004){ref-type="fig"}. The common odds ratio obtained was 2.2 (95% CI 1.6--3.0), p\<0.001. Another subgroup analysis ([Fig 4B](#pntd.0005153.g004){ref-type="fig"}) was based on studies that used brain computer tomography (n = 8). This gave a common odds-ratio of 3.2, (95% CI 2.5--4.1, p\<0.001). The third subgroup analysis, [Fig 4C](#pntd.0005153.g004){ref-type="fig"}, was based on the methods used to confirm epilepsy (n = 13), and gave a common odds ratio of 1.9 (95% CI 1.2--3.0), p\<0.001. We also performed an analysis by continent, showing that the effect was quite similar around the world ([Fig 3](#pntd.0005153.g003){ref-type="fig"}).

![Various subgroup meta-analyses (EITB: Fig 4A, CT scan: Fig 4b; best studies: Fig 4c) assessing the association between CC and epilepsy in Latin America, Asia and Africa: OR (odds ratio) of each study and common OR estimated using a random effects model.](pntd.0005153.g004){#pntd.0005153.g004}

Etiologic fraction {#sec015}
------------------

The etiologic fraction was estimated to be 63.0% (95% CI: 61.4--64.5) in the exposed group among the population. In other words, 63% of epilepsies were reportedly due to CC.

Discussion {#sec016}
==========

Our work was based on 37 studies conducted in many regions of Latin America, Asia and Africa. Particular efforts were made to identify studies by searching many databases and sources, including those that do not have a large international readership or were not in English. However, published information was available from only 23 countries, suggesting an evident information gap (see [Fig 2](#pntd.0005153.g002){ref-type="fig"}).

A substantial proportion of these publications (n = 11) reported hospital-based studies, four were performed in health centers or medical clinics and another in a very specific population of mine-workers. There is a need to conduct well-designed interventions with appropriate methodology and to use validated tools to improve data quality, thereby reducing basic epidemiological biases. The lack of a control group, even in analytic cross-sectional studies, made it impossible to probe the association between this CNS helminthic infection and late-onset epilepsy by itself (i.e. ELISA or EITB for cysticercosis tested in PWE vs general population). This is one reason why several wide-scale or hospital studies were not included in this meta-analysis \[[@pntd.0005153.ref014],[@pntd.0005153.ref015],[@pntd.0005153.ref016]\]. This type of study is also vulnerable to selection bias, particularly in rural areas, as epilepsy is stigmatized and may not also be visible (partial, mild seizures) or reported \[[@pntd.0005153.ref017]\]. The remaining 21 studies were population-based that did include a control group.

The association between CC and epilepsy was statistically significant in only 19 studies, (Tables [1](#pntd.0005153.t001){ref-type="table"} and [2](#pntd.0005153.t002){ref-type="table"}) and nearly significant in two studies. The odds ratios ranged from 0.2--25.4, and the *a posteriori* statistical power from 4.5% to 100.0% ([Table 3](#pntd.0005153.t003){ref-type="table"}). This wide variability could in part be due to non-adjustment of one or several other factors responsible for epilepsy occurrence. Many other factors, such as family predisposition, childbirth problems or head trauma, could lead to epilepsy and almost all studies failed to take into account all of these possible factors. Data elsewhere also support evidence that while in some populations there is a positive association between CC and epilepsy \[[@pntd.0005153.ref012]\], in other studies conducted at a similar point of time these associations are absent \[[@pntd.0005153.ref018]\]. Moreover, several studies with positive association between CC and epilepsy have their fair share of inconsistencies as well. For instance, one study in Burundi used an unmatched case-control study design \[[@pntd.0005153.ref012]\] in which there were fewer control subjects than cases and controls were recruited from the same families as the cases.

10.1371/journal.pntd.0005153.t003

###### Results obtained in studies looking for an association between cysticercosis and epilepsy classified by continent and sub-continent.

![](pntd.0005153.t003){#pntd.0005153.t003g}

                                                                                        PWE    PWOE   PWE CC+   PWOE CC+   SP                  
  ------------------------------------------------------ --------- -------------------- ------ ------ --------- ---------- ----- ------ ------ -------------------
  Chopra, 1981 \[[@pntd.0005153.ref022]\]                Asia      Southern Asia        771    98     267       25.7       2     2      100    25.4 (6.2--104.0)
  Maldonado, 1986 \[[@pntd.0005153.ref011]\]             Africa    Eastern Africa       240    385    40        16.7       19    5      99.9   3.9 (2.2--6.8)
  Mignard, 1986 \[[@pntd.0005153.ref023]\]               Africa    Eastern Africa       242    385    45        18.6       32    8.3    96.9   2.5 (1.6--4.1)
  Dumas, 1989 \[[@pntd.0005153.ref024]\]                 Africa    Western Africa       88     1439   27        30.7       98    6.8    100    6.1 (3.7--10.0)
  Gracia, 1990 \[[@pntd.0005153.ref025]\]                America   Central America      19     36     1         5.3        1     2.8    6.6    1.9 (0.1--32.9)
  Dansey, 1992 \[[@pntd.0005153.ref026]\]                Africa    South Africa         165    138    63        38.2       20    14.5   99.5   3.6 (2.1--6.4)
  Nzisabira, 1992 \[[@pntd.0005153.ref027]\]             Africa    Eastern Africa       98     30     40        40.8       1     3.3    96.9   20.0 (2.6--152.9)
  Sarti, 1992 \[[@pntd.0005153.ref028]\]                 America   North America        16     1533   5         31.3       162   10.6   67.8   3.9 (1.3--11.2)
  Garcia, 1993 \[[@pntd.0005153.ref029]\]                America   South America        2667   750    108       4.1        16    2.1    66.4   5.0 (2.2--11.4)
  Kong, 1993 \[[@pntd.0005153.ref030]\]                  Asia      Eastern Asia         189    309    22        11.6       8     2.6    98.6   1.9 (1.1--3.3)
  Bouteille, 1994 \[[@pntd.0005153.ref031]\]             Africa    Western Africa       22     1421   2         9.1        55    3.9    21.2   2.5 (0.6--10.9)
  Theis, 1994 \[[@pntd.0005153.ref032]\]                 Asia      South-Eastern Asia   74     746    10        13.5       94    12.6   4.5    1.1 (0.5--2.2)
  Aranda-Alvarez, 1995 \[[@pntd.0005153.ref033]\]        America   North America        46     854    3         6.5        6     0.7    92.7   9.9 (2.4--40.8)
  Grill, 1996 \[[@pntd.0005153.ref034]\]                 Africa    Eastern Africa       256    113    153       59.8       30    26.5   100    4.1 (2.5--6.7)
  Andriantsimahavandy, 1997 \[[@pntd.0005153.ref008]\]   Africa    Eastern Africa       104    104    33        31.7       14    13.5   88.6   3.0 (1.5--6.0)
  Handali, 1997 \[[@pntd.0005153.ref035]\]               Asia      South-Eastern Asia   241    260    163       67.6       215   82.7   99.2   0.4 (0.3--0.7)
  Newell, 1997 \[[@pntd.0005153.ref012]\]                Africa    Eastern Africa       103    72     12        11.7       2     2.8    56.8   4.6 (1.0--21.3)
  Cruz, 1999 \[[@pntd.0005153.ref037]\]                  America   South America        26     118    14        53.8       17    14.4   99.4   7.0 (2.7--17.5)
  Correa, 1999 \[[@pntd.0005153.ref036]\]                America   North America        68     133    15        22.1       17    12.8   38     1.9 (0.9--4.2)
  Balogou, 2000 \[[@pntd.0005153.ref038]\]               Africa    Western Africa       115    1343   12        10.4       37    2.8    99.1   4.1 (2.1--8.1)
  Mittal, 2001 \[[@pntd.0005153.ref039]\]                Asia      Southern Asia        1881   50     196       10.4       1     2      96.1   5.7 (0.8--41.5)
  Nicoletti, 2002 \[[@pntd.0005153.ref013]\]             America   South America        113    233    22        19.5       27    11.6   47     1.8 (1.0--3.4)
  Macharia, 2002 \[[@pntd.0005153.ref040]\]              Africa    Eastern Africa       99     124    5         5.1        3     2.4    19.1   2.2 (0.5--9.2)
  Rakatobe, 2002 \[[@pntd.0005153.ref041]\]              Africa    Eastern Africa       99     107    2         2          13    12.1   72.4   0.2 (0.1--0.7)
  Nsengiyumva, 2003 \[[@pntd.0005153.ref006]\]           Africa    Eastern Africa       324    648    193       59.6       204   31.5   100    3.2 (2.4--4.2)
  Dongmo, 2004 \[[@pntd.0005153.ref042]\]                Africa    Middle Africa        93     81     17        18.3       12    14.8   9.3    1.3 (0.6--2.9)
  Del Brutto, 2005 \[[@pntd.0005153.ref043]\]            America   South America        19     19     5         26.3       1     5.3    42.8   6.4 (0.7--61.5)
  Montano, 2005 \[[@pntd.0005153.ref044]\]               America   South America        39     111    15        38.5       26    23.4   41.8   2.0 (0.9--4.5)
  Li, 2006 \[[@pntd.0005153.ref045]\]                    Asia      Eastern Asia         55     445    9         16.4       11    2.5    99.9   7.7 (3.0--19.6)
  Tran, 2007 \[[@pntd.0005153.ref046]\]                  Asia      South-Eastern Asia   31     124    1         3.2        6     4.8    5.2    0.7 (0.1--5.7)
  Prasad, 2008 \[[@pntd.0005153.ref047]\]                Asia      Southern Asia        60     107    29        48.3       31    28.9   70.9   2.3 (1.2--4.4)
  Winkler, 2009 \[[@pntd.0005153.ref010]\]               Africa    Eastern Africa       212    198    38        17.9       10    5.1    98.2   4.1 (2.0--8.5)
  Secka, 2010 \[[@pntd.0005153.ref048]\]                 Africa    Western Africa       210    420    1         0.5        1     0.2    6.6    2.0 (0.1--32.2)
  Nitiéma, 2012 \[[@pntd.0005153.ref049]\]               Africa    Western Africa       39     814    5         12.9       28    3.4    67.1   4.1 (1.5--11.4)
  Singh, 2012 \[[@pntd.0005153.ref050]\]                 Asia      Southern Asia        106    106    27        25.5       13    12     77.7   2.4 (1.2--5.1)
  Elliott, 2013 \[[@pntd.0005153.ref051]\]               Africa    Middle Africa        249    245    11        4.4        13    53     7.6    0.8 (0.4--1.9)
  Ngugi, 2013 \[[@pntd.0005153.ref052]\]                 Africa    Eastern Africa       533    835    15        28.1       18    21.5   52.7   1.3 (0.7--2.6)

\*Result = 0 in the study, modified to calculate the odds ratio, otherwise OR independent, SP: a posteriori statistical power

OR: Odds ratio, PWE + CC: people with epilepsy affected by cysticercosis, PWE---CC: people with epilepsy not affected by cysticercosis,

PWOE + CC: people without epilepsy affected by cysticercosis, PWOE--CC: people without epilepsy unaffected by cysticercosis

Overall, the global OR from 37 studies was estimated to be 2.7 with a 95% confidence interval of 2.1 to 3.6. This degree of association conforms to individual studies conducted elsewhere \[[@pntd.0005153.ref008]\]. Another review from SSA yielded an OR of 3.4 \[[@pntd.0005153.ref007]\].

Although we did not conduct any analyse based on the type of epilepsy, the literature suggests, although again not without exceptions, a stronger association of CC with late-onset epilepsy and partial seizures\[[@pntd.0005153.ref004]\]. Another issue that can be raised is the temporality. We cannot be sure if seizures actually predated infection as several of our studies (see above) were cross-sectional surveys. Given the challenges in the availability of reliable patient records in most LMICs and excessive reliance on backward patient reporting about exposures to risk factors, even within case-control studies, it is not always and possible to confidently assess the temporality of this exposure before epilepsy becomes visible. \[[@pntd.0005153.ref019]\].

Two different serological tests to detect *antibodies T solium* in serum were applied in 27/37 (72.97%) studies. In field conditions, EITB-LLGP (known as western blot or immunoblot) is a useful tool to identify exposure, but does not discriminate between active or inactive lesions. In the clinical setting, a positive EITB-LLGP can support a diagnosis of NCC when there are suggestive images on brain CT scan or MRI. The sensitivity of this test is reported to be 98% with 100% specificity \[[@pntd.0005153.ref020]\]; however, the sensitivity is much lower for NCC with less than 2 parenchymal cysts or for calcified NCC. This is contrast to ELISA, which is specific to viable cyst infection (93.7%) but much less sensitivity in single-lesion\[[@pntd.0005153.ref053]\]. The prevalence of viable NCC cases are low in field conditions (most of them asymptomatic) making this tool unhelpful for epidemiological interventions. Detection of CC would, therefore, depend on the type, accuracy, cost and availability of these tests. Studies that used EITB antibody detection gave a common OR of 1.9, much lower than the global OR obtained by taking into account all 37 studies. Other factors may also reduce the strength of any association between serologically-defined CC and other disease conditions, including *a)* high background seroprevalence in the general population (usually considered to be 10--25%), and *b)* many individuals with calcified CC become seronegative over the years \[[@pntd.0005153.ref005]\].

The gold standard tool for determining CC exposure is to demonstrate the parasite in the CNS, by biopsy, although this is not without risk. Modern neuroimaging can provide strong evidence of NCC and should be done for both cases and controls. As shown above, many studies do not include neuroimaging due to cost, radiation exposure, and guidelines. Of the 37 studies reviewed, only eight used CT in both cases and controls; in these, the common OR reached 3.2, a value close to, but higher than, that obtained by considering all studies.

Based on our 37 studies, the etiologic fraction was estimated to be 63% among the exposed group in the population. This indicates an excellent opportunity to prevent a large fraction of late onset epilepsy given that CC can be prevented by controlling transmission of T. solium \[[@pntd.0005153.ref021]\]. This study suggesst that adequate control measures and surveillance of CC in endemic regions should be key issues in preventing late-onset epilepsy in tropical regions.

Perspectives {#sec017}
------------

We propose that future field interventions should meet basic requirements to be more useful:

-   Adequate design and use of validated surveys in community-based studies

-   Case-control studies with high levels of exposure to CC

-   Sufficient statistical power by recruiting adequate numbers of people with epilepsy and controls

-   Matching of controls by sex, age and location

-   Computed tomography of the brain without contrast and serological assays (Ag-ELISA and EITB) should be performed for all included subjects.

-   Use of International League Against Epilepsy guidelines for epidemiological studies to standardized concepts of classification of epilepsy (ILAE 1993).

-   Include family trees to assess familial history of seizures.

-   Efforts should be made to assess all other possible risk factors for epilepsy.

Conclusions {#sec018}
===========

Cysticercosis is an active helminthic infection common in tropical regions. Many questions are still unanswered and there are still many limitations in epidemiological base-studies. Based on the current data, NCC is significantly associated with symptomatic epilepsy in low and middle-income countries. However, the strength of this association certainly varies depending on the transmission intensity (rural areas, poor sanitation, lack of potable water, etc). More meta-analyses that are meaningful require good quality studies in tropical regions following certain basic methodological requirements listed above. Finally, epilepsy attributable to CC is preventable. There is a need to focus our efforts on research, control and prevention of CC to avoid increased costly neurological morbidity of this zoonotic disease.
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